Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57 results about "Metalloprotease inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Metalloprotease inhibitors are cellular inhibitors of the Matrix metalloproteinases (MMPs). MMPs belong to a family of zinc-dependent neutral endopeptidases. These enzymes have the ability to break down connective tissue. The expression of MMPs is increased in various pathological conditions like inflammatory conditions, metabolic bone disease, to cancer invasion, metastasis and angiogenesis. Examples of diseases are periodontitis, hepatitis, glomerulonephritis, atherosclerosis, emphysema, asthma, autoimmune disorders of skin and dermal photoaging, rheumatoid arthritis, osteoarthritis, multiple sclerosis, Alzheimer's disease, chronic ulcerations, uterine involution, corneal epithelial defects, bone resorption and tumor progression and metastasis. Due to the role of MMPs in pathological conditions, inhibitors of MMPs may have therapeutic potential. Several other proteins have similar inhibitory effects, however none as effective (netrins, procollagen C-terminal proteinase enhancer (PCPE), reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and tissue factor pathway inhibitor (TFPI-2)). They might have other biological activities which have yet been fully characterised.
Substituted bis-amide metalloprotease inhibitors
This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.
Owner:ALANTOS PHARMA HLDG INC
Combination therapy for the treatment of cancer
The present invention provides methods of treating cancer comprising treating a patient in need thereof with hormone therapy and administering to the patient a therapeutically effective amount of at least one metalloprotease inhibitor. The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of at least one hormone therapy agent, at least one metalloprotease inhibitor, and a pharmaceutically acceptable carrier.
Owner:INCYTE HLDG CORP
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Hydroxamic acid derivatives as metalloprotease inhibitors
The present invention provides compounds of Formula I or II: salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions.
Owner:INCYTE CORP
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.
Owner:NOLTE BERT +9
Treatment of CNS tumors with metalloprotease inhibitors
InactiveUS6025333AAvoid environmentIncrease the areaOrganic active ingredientsNervous disorderAbnormal tissue growthNervous system
The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include central nervous system myelin associated proteins and metalloproteases associated with glioblastoma cells and other malignant tumors which can metastasize to the brain. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system. The present invention is also directed to inhibitors of the metalloproteases. Such inhibitors in combination with the CNS myelin associated inhibitory proteins can be used in the treatment of malignant tumors.
Owner:ZURICH UNIV OF
Methods and compositions for controlling ectoparasites
ActiveUS20060178404A1Preventing breeding cycleInhibiting ectoparasite egg hatchingBiocideGroup 8/9/10/18 element organic compoundsSulfurHeteroatom
A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and / or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and / or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and / or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.
Owner:DR REDDYS LAB SA
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrido or R1 and R2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.
Owner:BARTA THOMAS +19
Metalloprotease inhibitors containing a heterocyclic moiety
The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a modified benzoxazine moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Heterocyclic derived metalloprotease inhibitors
InactiveUS20080103129A1Useful in treatmentBiocideSenses disorderDiseaseMatrix metalloproteinase inhibitor
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
Owner:JANSSEN PHARMA NV
Metalloprotease inhibitors containing a heterocyclic moiety
The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and / or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Metalloprotease inhibitors containing a heterocyclic moiety
The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a modified benzoxazine moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Combination therapy for anthrax using antibiotics and protease inhibitors
The invention provides compositions for treatment anthrax infection. The composition comprises a therapeutically effective amount of at least one B. anthracis metalloprotease inhibitor. The composition may further include an antimicrobial agent. The invention also provides methods for treating anthrax infection in a human or an animal subject. The method comprises administering to the subject a therapeutically effective amount of a composition of the present invention.
Owner:AFG BIOSOLUTIONS
Antineoplastic invasion transfer function of snake venom metalloprotease inhibitors BJ46a and uses thereof
InactiveCN101429525AInhibitory activityObvious anti-tumor invasion and metastasis effectPeptide/protein ingredientsGenetic material ingredientsAbnormal tissue growthIn vivo
The invention discloses a snake venom metal protease inhibitor BJ46a capable of resisting attack and transference of tumor and application thereof, and belongs to the field of medical organism. In the invention, according to the BJ46a gene sequence (AF294836) in GenBank, the BJ46a full gene is designed and synthesized. An expression vector cloned to baculovirus can generate the recombined BJ46a protein capable of inhibiting the activity of the substrate metal protease in Sf9 insect cells, and in vivo and in vitro experiments show that the BJ46a protein has the functions of resisting the attack and transference of melanoma cells B16. The inhibitor adopts the genetic transfection technique, and can establish B16 / pcDNA3.1HisC-BJ46a cell strains with stable transfection, and the in vivo and in vitro experiments prove that the BJ46a can inhibit the attack and transference of B16 cells at the gene level. The inhibitor is applied to preventing and treating the attack and transference of tumor, and has great application prospect.
Owner:FUJIAN MEDICAL UNIV
Methods and compositions for controlling ectoparasites
ActiveUS7812163B2Preventing breeding cycleInhibiting ectoparasite egg hatchingBiocideGroup 8/9/10/18 element organic compoundsSulfurNitrogen
A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and / or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and / or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and / or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.
Owner:DR REDDYS LAB SA
Anti-tumor-stroma metalloprotease inhibitor
InactiveCN101559076AStrong inhibitory activitySimple structureHeavy metal active ingredientsInorganic phosphorous active ingredientsTumor stromaDepressant
The invention discloses a use of third-valence metal salt as MMPs inhibitor, the third-valence metal salt is free third-valence metal salt or third-valence metal composition. The third-valence metal salt is third-valence rare earth salt or third-valence transition metal salt or third-valence major-group metal salt. Compared with prior MMPs inhibitor, the third-valence metal salt of the invention has relatively strong MMPs inhibiting activity; furthermore, the third-valence metal salt of the invention has simple structure, low cost and convenient availability.
Owner:NORTHWEST UNIV(CN) +1
Alpha-amido acyl-ring imide peptoid metalloprotease inhibitor and application thereof
InactiveCN101538311AHigh selectivityGood compatibilityNervous disorderDipeptide ingredientsDiseaseImide
The invention relates to an alpha-amido acyl-ring imide peptoid metalloprotease inhibitor and an application thereof. The invention provides a powerful peptoid metalloprotease inhibitor which embodies outstanding selectivity between endopeptidases and exopeptidases so as to effectively treat diseases expressed by abnormal metalloprotease activity. Specifically, the invention relates to a peptoid compound with a structure of a general formula (I) and salt thereof acceptable on pharmacy. The invention also relates to a medical composition of the peptoid compound with the structure of the formula (I) and the pharmacy application thereof.
Owner:SHANDONG UNIV
Pyrrolidinyl metalloprotease inhibitor and its application
The present invention is pyrrolidinyl matrix metalloprotease inhibitor and its application. One kind of powerful matrix metalloprotease inhibitor is provided to treat disease with abnormal matrix metalloprotease activity expression effectively. Specifically, the present invention relates to the compound, various optical isomers, pharmaceutically acceptable salts, solution and precursor medicine. The present invention also relates to their pharmaceutical use.
Owner:SHANDONG UNIV
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and / or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
Owner:BLUHM HARALD +6
Heterocyclic derived metalloprotease inhibitors
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula:and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
Owner:JANSSEN PHARMA NV
Combination therapy for the treatment of cancer
The present invention provides methods of treating cancer comprising treating a patient in need thereof with hormone therapy and administering to the patient a therapeutically effective amount of at least one metalloprotease inhibitor. The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of at least one hormone therapy agent, at least one metalloprotease inhibitor, and a pharmaceutically acceptable carrier.
Owner:INCYTE HLDG CORP
Compounds and methods for the treatment of pain and other diseases
ActiveUS20110230452A1Enhanced and exaggerated sensitivityBiocideNervous disorderDiseaseMetabolic stability
The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and / or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors for the treatment of pain and other diseases. Additionally, the present invention relates to methods for treating pain, addiction and / or withdrawal symptoms in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.
Owner:AQUILUS PHARMA
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and / or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
Owner:HOCHGURTEL MATTHIAS +5
Cyclin imide peptidyl metalloprotease inhibitor and its application
InactiveCN100560568CProlong the action timeInhibitory activityOrganic active ingredientsDipeptidesDiseaseCyclin
Cyclic imide peptide metalloprotease inhibitors and applications thereof. The invention provides a class of potent peptide-like metalloprotease inhibitors, which exhibit remarkable selectivity between endopeptidase and exopeptidase, and can effectively treat diseases with abnormal expression of metalloprotease activity. Specifically, the present invention relates to a peptoid compound having a structure of general formula (I), and various optical isomers, pharmaceutically acceptable salts, solvates and prodrugs thereof. The present invention also relates to a pharmaceutical composition containing the structural peptoid compound of formula (I) and its pharmaceutical application.
Owner:SHANDONG UNIV
Heterotricyclic metalloprotease inhibitors
The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and / or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Methods and compositions for controlling ectoparasites
A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and / or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and / or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and / or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.
Owner:HATCHTECH PTY LTD
Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
InactiveUS8329751B2Improve stabilityImprove abilitiesAntibacterial agentsBiocideArylDegenerative Disorder
The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having formula (I) belowwherein R, R1, R2, R3, R4, R5, n and m have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.
Owner:BRACCO IMAGINIG SPA
Heterobicyclic metalloprotease inhibitors
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
Owner:ALANTOS PHARMA HLDG INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com